Los Angeles region-based City of Hope is a leading research site for a chimeric antigen receptor (CAR) T cell clinical trial focusing on patients with HER2 positive breast cancer that has spread to the brain. Conducted in an outpatient setting, City of Hope will be the first to use intraventricular delivery of CAR T cells directly into the patients’ brains. The study’s research site staff and sponsor (Mustang Bio Inc.) seek to test the safety and efficacy of the CAR T cell therapy for patients that have no other available options.
City of Hope is a private, not for profit clinical research center, hospital and graduate medical school in Duarte, California. It has been designated a Comprehensive Cancer Center by the National Cancer Institute. https://en.
City of Hope has ranked as one of the nation’s best cancer hospitals and is a founding member of National Comprehensive Cancer Network. https://en.wikipedia.
Participating commercial sponsor Mustang Biotech has a sole licensing agreement with City of Hope–see link: http://www.mustangbio.
com/fortress-biotech- announces-that-its-subsidiary- mustang-bio-enters-into- license-agreements-with-city- of-hope-for-novel-car-t- immunotherapies/
Saul Priceman, PhD